Filtyp
Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su
Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye
Please wait... Address Medicon VillageBuilding 406Scheelevägen 2 223 81 LundSweden
https://www.createhealth.lth.se/contact - 2026-09-09
CREATE Health, inaugurated in 2006 with a focus on precision medicine, is a strategic centre for translational research focusing on the early diagnosis and prognosis of cancer, as well as the development of novel treatment strategies. Our vision: To accelerate translation of breakthrough therapies and diagnostics into clinical practice, improving outcomes for today´s cancer patients while building
https://www.createhealth.lth.se/about - 2026-09-09
Our research accompanies the entire patient journey, from initial diagnosis through treatment and companion diagnostics to quality-of-life enhancement during and after cancer. We deliver translational solutions that start from specific clinical needs identified by our clinical partners, leveraging novel technological approaches to accelerate implementation into the clinic with dramatically reduced
https://www.createhealth.lth.se/research - 2026-09-09
Lund University research projects Currently at Lund Univeristy, ten research projects are driven by ten Principle Investigators from the Faculty of Engineering (LTH) and the Faculty of Medicine. The common goal of all of them is to deepen knowledge and fast forward innovations in cancer diagnostics and treatment. Molecular characterisation of breast cancer: biomarkers of risk, prognosis and treatm
https://www.createhealth.lth.se/research/research-projects - 2026-09-09
Please wait...
https://www.createhealth.lth.se/contact/principal-investigators - 2026-09-09
In 2025, CREATE Health Translational Cancer Center received a donation from the Mrs Berta Kamprad’s Cancer Foundation of 420 million SEK. This is the single largest donation to Lund University, since its founding in 1666. The funds are distributed over a five-year period and dedicated to translational cancer research within the L2CancerBridge programme.Other previous and current funding for the CR
https://www.createhealth.lth.se/about/funding - 2026-09-09
L2CancerBridge is a groundbreaking collaborative cancer research programme that bridges two of Europe's leading research institutions: CREATE Health at Lund University, Sweden, and the Swiss Cancer Centre at EPFL in Lausanne, Switzerland. The L2CancerBridge programme exemplifies how international partnerships can accelerate cancer research breakthroughs. By combining the expertise and resources of
https://www.createhealth.lth.se/research/l2cancerbridge-programme-collaborative-excellence - 2026-09-09
Please wait...
https://www.createhealth.lth.se/contact/antibody-unit - 2026-09-09
Antibody Initiative Advances in antibody engineering have revolutionised cancer therapy, and biological drugs now constitute a cornerstone of frontline treatment across most cancer subtypes. We drive continued innovation and clinical success by continuously enhancing local capabilities in Lund to develop tailored molecules for targeted cancer treatment- specific antigens, immune checkpoints, or as
https://www.createhealth.lth.se/research/technologies - 2026-09-09
LUNARC. Read more about LUNARC computing resources at Lund UniversityeSSENCE. Read more about eSSENCE, The e-Science Collaboration at Lund UniversityCOMPUTE. Read more about COMPUTE at Lund UniversityLINXS. Read more about LINXS, Institute of advanced neutron and x-ray science
https://www.compchem.lu.se/research/associated-activities - 2026-09-09
Computational Chemistry promotes the usage of X-ray and neutron scattering techniques and provides the researchers at LU with a facility where it is possible to measure and simulate macromolecules in solution and serve as an entry environment to the large scale infrastructures. Computational Cehmistry also promotes software for classical molecular simulations, multireference quantum chemistry calc
https://www.compchem.lu.se/infrastructure - 2026-09-09
https://www.compchem.lu.se/staff - 2026-09-09
9 October 2026 15:15 to 16:00 | Seminar Ellen Nilsson, Master student by Computational Chemistry, Lund University will present her thesisTitel: Investigating the Reproducibility of QM/MM Calculations for Sulfite OxidaseWhen: October 9, 2026 15:15-16:00Where: Kemicentrum, Lecturehall KC:G About the eventLocation:Lecturehall KC:GContact:ulf [dot] ryde [at] compchem [dot] lu [dot] se Save the event t
https://www.compchem.lu.se/calendar/master-thesis-presentation-ellen-nilsson-0 - 2026-09-09
Faunus Faunus is a free, object oriented library for classical molecular simulations written in C++/Python. Besides handling macromolecular solutions in various ensembles such as NVT, μVT, NPT, Faunus also covers more excotic topics such as proton fluctuations, arbitrary parallel tempering and hyperspherical geometry.More information on the Faunus website Molcas MOLCAS is a quantum chemistry softw
https://www.compchem.lu.se/infrastructure/software - 2026-09-09
In 2021 Infrastructure Call at Lund University, we were gratefully approved funding from LU Central, the Science Faculty, and the Faculty of Engineering for purchasing a Solution X-ray Scattering Instrument for Life Science and Soft Matter, short-name the BioSAXS. Our vision is to promote the usage of X-ray and neutron scattering techniques and provide the researchers at LU with a facility where i
https://www.compchem.lu.se/infrastructure/biosaxs-instrument - 2026-09-09
Current vacanciesCurrent job vacancies at the Division of Computational Chemistry (Varbi)To apply for a vacant position, you need an account in Lund University’s recruitment system, Varbi.How to apply for a position (Lund University’s website)
https://www.compchem.lu.se/about/job-vacancies - 2026-09-09
Vem kan vara med i DORIS-studien?Vad innebär deltagande i studien?Hur kommer jag med i studien?Vem kan vara med i DORIS-studien?Barn som ingår i neonatalvårdens nationella uppföljningsprogram och som bor i Södra Sveriges sjukvårdsregion, ska erbjudas deltagande i studien.Här ingår: Barn som är föds extremt för tidigt, dvs. innan graviditetsvecka 28Barn med en extremt låg födelsevikt (<3SD)Barn som
https://www.doris.lu.se/om-doris - 2026-09-09
Deltagande i DORIS-studien innebär att vi följer ditt barns utveckling med nogsam informationsinhämtning under de första två åren. Du får fylla i skattningsformulär när ditt barn är 6, 12 och 18 månaders ålder. Formulären skickas till din hemadress med post och ifyllda formulär ska returneras till oss i ett svarskuvert. Vid 2 år och 5,5 års ålder kallas barnet för sedvanligt besök på Neonatalmott
https://www.doris.lu.se/om-doris/vad-innebar-deltagande-i-studien - 2026-09-09
